TY - JOUR
T1 - Customizing local and systemic therapies for women with early breast cancer
T2 - the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021
AU - Panelists of the St Gallen Consensus Conference
AU - Burstein, H. J.
AU - Curigliano, G.
AU - Thürlimann, B.
AU - Weber, W. P.
AU - Poortmans, P.
AU - Regan, M. M.
AU - Senn, H. J.
AU - Winer, E. P.
AU - Gnant, M.
AU - Aebi, Stephan
AU - André, Fabrice
AU - Barrios, Carlos
AU - Bergh, Jonas
AU - Bonnefoi, Herve
AU - Bretel Morales, Denisse
AU - Brucker, Sara
AU - Burstein, Harold
AU - Cameron, David
AU - Cardoso, Fatima
AU - Carey, Lisa
AU - Chua, Boon
AU - Ciruelos, Eva
AU - Colleoni, Marco
AU - Curigliano, Giuseppe
AU - Delaloge, Suzette
AU - Denkert, Carsten
AU - Dubsky, Peter
AU - Ejlertsen, Bent
AU - Fitzal, Florian
AU - Francis, Prudence
AU - Galimberti, Viviana
AU - Gamal El Din Mohamed Mahmoud, Hebatallah
AU - Garber, Judy
AU - Gnant, Michael
AU - Gradishar, William
AU - Gulluoglu, Bahadir
AU - Harbeck, Nadia
AU - Huang, Chiun Sheng
AU - Huober, Jens
AU - Ilbawi, Andre
AU - Jiang, Zefei
AU - Johnston, Steven
AU - Lee, Eun Sook
AU - Loibl, Sibylle
AU - Morrow, Monica
AU - Partridge, Ann
AU - Piccart, Martine
AU - Poortmans, Philip
AU - Prat, Aleix
AU - Vaz Luis, Inez
N1 - Publisher Copyright:
© 2021
PY - 2021/10/1
Y1 - 2021/10/1
N2 - The 17th St Gallen International Breast Cancer Consensus Conference in 2021 was held virtually, owing to the global COVID-19 pandemic. More than 3300 participants took part in this important bi-annual critical review of the ‘state of the art’ in the multidisciplinary care of early-stage breast cancer. Seventy-four expert panelists (see Appendix 1) from all continents discussed and commented on the previously elaborated consensus questions, as well as many key questions on early breast cancer diagnosis and treatment asked by the audience. The theme of this year's conference was ‘Customizing local and systemic therapies.’ A well-organized program of pre-recorded symposia, live panel discussions and real-time panel voting results drew a worldwide audience of thousands, reflecting the far-reaching impact of breast cancer on every continent. The interactive technology platform allowed, for the first time, audience members to ask direct questions to panelists, and to weigh in with their own vote on several key panel questions. A hallmark of this meeting was to focus on customized recommendations for treatment of early-stage breast cancer. There is increasing recognition that the care of a breast cancer patient depends on highly individualized clinical features, including the stage at presentation, the biological subset of breast cancer, the genetic factors that may underlie breast cancer risk, the genomic signatures that inform treatment recommendations, the extent of response before surgery in patients who receive neoadjuvant therapy, and patient preferences. This customized approach to treatment requires integration of clinical care between patients and radiology, pathology, genetics, and surgical, medical and radiation oncology providers. It also requires a dynamic response from clinicians as they encounter accumulating clinical information at the time of diagnosis and then serially with each step in the treatment plan and follow-up, reflecting patient experiences and treatment response.
AB - The 17th St Gallen International Breast Cancer Consensus Conference in 2021 was held virtually, owing to the global COVID-19 pandemic. More than 3300 participants took part in this important bi-annual critical review of the ‘state of the art’ in the multidisciplinary care of early-stage breast cancer. Seventy-four expert panelists (see Appendix 1) from all continents discussed and commented on the previously elaborated consensus questions, as well as many key questions on early breast cancer diagnosis and treatment asked by the audience. The theme of this year's conference was ‘Customizing local and systemic therapies.’ A well-organized program of pre-recorded symposia, live panel discussions and real-time panel voting results drew a worldwide audience of thousands, reflecting the far-reaching impact of breast cancer on every continent. The interactive technology platform allowed, for the first time, audience members to ask direct questions to panelists, and to weigh in with their own vote on several key panel questions. A hallmark of this meeting was to focus on customized recommendations for treatment of early-stage breast cancer. There is increasing recognition that the care of a breast cancer patient depends on highly individualized clinical features, including the stage at presentation, the biological subset of breast cancer, the genetic factors that may underlie breast cancer risk, the genomic signatures that inform treatment recommendations, the extent of response before surgery in patients who receive neoadjuvant therapy, and patient preferences. This customized approach to treatment requires integration of clinical care between patients and radiology, pathology, genetics, and surgical, medical and radiation oncology providers. It also requires a dynamic response from clinicians as they encounter accumulating clinical information at the time of diagnosis and then serially with each step in the treatment plan and follow-up, reflecting patient experiences and treatment response.
KW - adjuvant
KW - genetic testing
KW - neoadjuvant
KW - radiation therapy
KW - surgery
KW - survivorship
UR - http://www.scopus.com/inward/record.url?scp=85112530035&partnerID=8YFLogxK
U2 - 10.1016/j.annonc.2021.06.023
DO - 10.1016/j.annonc.2021.06.023
M3 - Article
C2 - 34242744
AN - SCOPUS:85112530035
SN - 0923-7534
VL - 32
SP - 1216
EP - 1235
JO - Annals of Oncology
JF - Annals of Oncology
IS - 10
ER -